

Formulary Update

July 2022

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since May 2022. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Sodium bicarbonate oral solution	Bidex® (sodium bicarbonate 8.4%)	9.2.1.2, 9.2.1.3	MCEG project
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Potassium permanganate	Included updated safety information regarding risk of inadvertent oral administration	13.11.6	Guideline update by British Association of Dermatologists
Ulipristal	Now in Preferred List alongside levonorgestrel for emergency contraception (EC)	7.3.5	Updated Sandyford EC guideline
Valaciclovir	Now available as treatment for recurrent herpes.	5.3.2.1	Formulary appeal